Acquisition of CorHepta - Schedule of Allocation of Consideration Transferred (Details) - USD ($) |
3 Months Ended | |
---|---|---|
Feb. 21, 2025 |
Mar. 31, 2025 |
|
Fair Value, Recurring [Member] | ||
Business Acquisition [Line Items] | ||
Fair value of consideration | $ 7,338,719 | |
CorHepta Pharmaceuticals [Member] | ||
Business Acquisition [Line Items] | ||
Cash | 49,633 | |
Current liabilities | (68,208) | |
Fair value of consideration | 7.4 | |
CorHepta Pharmaceuticals [Member] | In Process Research and Development [Member] | ||
Business Acquisition [Line Items] | ||
Acquired IPR&D | $ 7,357,294 | |
CorHepta Pharmaceuticals [Member] | Fair Value, Recurring [Member] | ||
Business Acquisition [Line Items] | ||
Fair value of consideration | $ 7,338,719 |
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|